|
|
Article: Immunicon Corporation Announces Presentation of Further Data on Circulating Tumor Cells in Metastatic Breast Cancer at the 2005 American Association of Clinical Oncology (ASCO) Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- May 16, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HUNTINGDON VALLEY, Pa., May 16 /PRNewswire-FirstCall/ -- Immunicon Corporation , a development-stage company developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer, announced the presentation of additional data from its clinical trial in metastatic breast cancer and the significance of circulating tumor cells (CTCs) in the blood of such patients undergoing treatment. An abstract entitled "Presence of circulating tumor cells (CTC[s]) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis," Abstract 524, was presented on Monday, May 16, 2005, from 9:00 ...